EPC-003
Glioblastoma
Phase 1Active
Key Facts
About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, USA, with an additional presence in Singapore. The company is focused on developing novel bispecific armored CAR-T cell therapies and immuno-modulators to treat solid tumors, a significant unmet medical need. Its core strategy leverages proprietary platforms for multi-antigen targeting and armored cell engineering to improve efficacy and durability. Elpis's lead programs target glioblastoma and a broad range of solid tumors, positioning it in the competitive but high-potential field of next-generation cell therapy.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |